Toripalimab

Definition

A humanized immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (programmed death-1; PD-1), with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, toripalimab binds to PD-1 and inhibits the binding of PD-1 to its ligands, programmed cell death-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2). This prevents the activation of PD-1 and its downstream signaling pathways. This may restore immune function through the activation of both T-cells and T-cell-mediated immune responses against tumor cells. PD-1, a transmembrane protein in the Ig superfamily that is expressed on activated T-cells, negatively regulates T-cell activation and effector function when activated by its ligands; it plays an important role in tumor evasion from host immunity.

Also known as Anti-PD-1 Monoclonal Antibody JS001, JS 001, JS-001, JS001, Loqtorzi, TAB 001, TAB-001, TORIPALIMAB, Toripalimab-tpzi, Tuoyi — per NCIT

Also identified as

• ATC L01FF13 per RXNORM
• NCIT NCIT:C131334 per NCIT
• SCTID 933451391000036109 per RXNORM
• UNII 8JXN261VVA per RXNORM

Indications

Organ Effects

5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.